Y-27632 dihydrochloride: Selective ROCK1/2 Inhibitor for Cytoskeletal and Stem Cell Research

Executive Summary. Y-27632 dihydrochloride is a potent, cell-permeable Rho-associated protein kinase (ROCK1 and ROCK2) inhibitor, exhibiting IC₅₀ values of 140 nM for ROCK1 and Ki of 300 nM for ROCK2, with >200-fold selectivity over related kinases (APExBIO, product page). By targeting the ROCK catalytic domain, it disrupts Rho-mediated actin stress fiber formation and modulates cell cycle progression from G1 to S phase (Mishra et al., 2024, DOI). Y-27632 enhances viability of stem cells, supports advanced workflows in cytoskeletal research, and suppresses tumor invasion in preclinical models. The compound is highly soluble (≥111.2 mg/mL in DMSO) and stable under standard laboratory storage conditions. Its integration into diverse cell culture and cancer models has made it an indispensable tool for dissecting the Rho/ROCK signaling axis.

Biological Rationale

Rho-associated coiled-coil kinases (ROCK1 and ROCK2) are central effectors in the Rho/ROCK signaling pathway. They regulate actin cytoskeleton organization, cell contractility, and cell cycle progression. Dysregulation of ROCK activity is implicated in pathological processes, including tumor invasion, metastasis, and abnormal stem cell differentiation (see related article). Y-27632 dihydrochloride enables precise, reproducible inhibition of ROCK1/2, facilitating mechanistic studies of cell morphology, migration, and contractility.

In the context of neurodegeneration, aberrant endo-lysosomal trafficking—regulated in part by cytoskeletal dynamics—is an early event in disease models such as Alzheimer's disease (Mishra et al., 2024, DOI). Tools like Y-27632 thus extend beyond cancer and stem cell biology, informing studies of vesicular transport and cellular stress responses.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride is a small-molecule inhibitor that binds to the ATP-binding site of ROCK1 and ROCK2. This interaction blocks kinase activity with an IC₅₀ of 140 nM for ROCK1 and a Ki of 300 nM for ROCK2 (APExBIO).

Key mechanistic effects include:

• Disruption of Rho-mediated actin stress fiber formation, reducing cellular contractility.
• Modulation of cell cycle transition from G1 to S phase via downstream signaling effects.
• Interference with cytokinesis, resulting in altered cell division outcomes.

Y-27632 demonstrates >200-fold selectivity over kinases such as protein kinase C (PKC), cAMP-dependent protein kinase (PKA), myosin light chain kinase (MLCK), and p21-activated kinase (PAK), minimizing off-target effects (APExBIO, product page).

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 in vitro with an IC₅₀ of 140 nM and ROCK2 with a Ki of 300 nM, demonstrating high potency and selectivity (APExBIO product page).
• In prostatic smooth muscle cells, Y-27632 reduces cell proliferation in a concentration-dependent manner (0.1–10 μM, 24–72 h incubation) (APExBIO).
• In mouse models, Y-27632 administration diminishes pathological tumor structures and suppresses invasion and metastasis by modulating actomyosin contractility (see related review).
• Y-27632 maintains human-induced pluripotent stem cell (hiPSC) viability during passage and single-cell dissociation (10 μM, 24 h) and reduces apoptosis (see stem cell workflow article).
• Endo-lysosomal dysfunction studies utilize Y-27632 to probe cytoskeletal contributions to vesicular trafficking and neuronal stress (Mishra et al., 2024, DOI).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is broadly applied in biomedical research:

• Cytoskeletal dynamics: Inhibition of Rho-mediated stress fiber formation in fibroblasts, epithelial, and neuronal cells.
• Stem cell culture: Enhancement of hiPSC and hESC survival during single-cell passage and cryopreservation.
• Cancer biology: Suppression of cell migration, invasion, and metastasis in tumor models.
• Cell proliferation and cytokinesis assays: Modulation of G1/S cell cycle progression and division fidelity.

Compared to prior reviews that outline basic selectivity and cytoskeletal effects, this article adds updated evidence from in vivo tumor models and the emerging use of Y-27632 in neurodegenerative research.

Common Pitfalls or Misconceptions

• Y-27632 is not a pan-kinase inhibitor; activity against non-ROCK kinases is minimal at research concentrations (<10 μM).
• Long-term culture with Y-27632 may alter cell differentiation potential; periodic withdrawal is recommended for stem cell protocols.
• Compound is not suitable for in vivo use at high doses without pharmacokinetic validation.
• Not effective in ROCK-independent forms of cell motility or invasion.
• Does not reverse established cytoskeletal defects once terminal differentiation has occurred.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid by APExBIO (SKU: A3008). It is soluble at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, and ≥52.9 mg/mL in water. Warming (37°C) or ultrasonic bath treatment improves dissolution (product page).

• Stock preparation: Prepare 10–100 mM in DMSO; store at –20°C (desiccated).
• Working concentrations: Typical cell culture protocols use 1–10 μM.
• Stability: Stock solutions are stable for several months at –20°C; avoid repeated freeze-thaw cycles.
• Storage: Solid form should be kept at ≤4°C, desiccated.
• Handling: For maximum reproducibility, filter-sterilize solutions and use freshly diluted aliquots.

This extends the epithelial contractility review by specifying exact solubility values and storage recommendations for translational workflows.

Conclusion & Outlook

Y-27632 dihydrochloride is established as a gold-standard, selective ROCK1/2 inhibitor with wide application in cytoskeletal, stem cell, and cancer research. Its high specificity, robust performance, and solubility profile make it an essential reagent for dissecting cell mechanics and signaling. Ongoing advances in neurodegeneration and organoid modeling underscore its expanding utility, while rigorous attention to dosing and cell-type context ensures optimal outcomes. For complete technical specifications, refer to the APExBIO Y-27632 dihydrochloride product page.